Advertisement
EW vs SYK
Which Stock Would AI Choose? Edwards Lifesciences (EW) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- EW, a leader in structural heart devices, boasts a market capitalization of approximately $46 billion, significantly smaller than SYK's $130 billion, reflecting SYK's broader diversification across orthopedics and neurotechnology.
- Recent year-to-date performance shows EW up 7.27%, outperforming SYK's 3.48% gain, amid strong procedural growth in transcatheter therapies for EW.
- SYK offers a dividend yield of 1.04%, appealing to income-focused investors, while EW reinvests in growth with no dividend.
- Forward P/E ratios indicate SYK at 22.57 versus EW's 27.40, suggesting relatively better valuation for SYK despite similar low betas around 0.94.
- Both stocks await Q1 2026 earnings, with EW's transcatheter mitral/tricuspid (TMTT) sales surging over 40% recently, and SYK advancing via vascular acquisitions.
Introduction
Edwards Lifesciences (EW) and Stryker (SYK) represent prominent players in the medical technology sector, specializing in innovative devices for cardiovascular and orthopedic procedures, respectively. This stock comparison analyzes their business models, recent market performance, and key metrics to aid investors and traders evaluating relative performance in the healthcare equipment space. With both companies navigating procedural volume growth amid economic uncertainties, professionals seeking growth-oriented medtech exposure or diversified stability will find insights into momentum, valuation, and sector positioning particularly relevant for portfolio decisions.
EW Overview and Recent Performance
Edwards Lifesciences Corporation (EW) focuses on structural heart technologies, particularly transcatheter aortic valve replacement (TAVR) systems like the SAPIEN family and emerging mitral/tricuspid solutions such as PASCAL and EVOQUE. In recent market activity, EW shares have traded around $80-81, within a 52-week range of $68.63-$87.89, reflecting resilience amid broader healthcare volatility. Year-to-date gains stand at 7.27%, supported by robust Q4 2025 results including over 40% growth in transcatheter mitral and tricuspid therapies (TMTT). Sentiment has been buoyed by procedural adoption and upcoming Q1 2026 earnings on April 23, though high trailing P/E (price-to-earnings) ratio of 43.67 tempers enthusiasm. Trailing twelve months (TTM) revenue reached $6.07 billion with EPS (earnings per share) of $1.81, underscoring growth potential in minimally invasive cardiology.
SYK Overview and Recent Performance
Stryker Corporation (SYK) is a diversified medical technology firm with strengths in orthopaedics, neurotechnology, MedSurg, and expanding vascular portfolios. Shares recently hovered near $338, in a 52-week range of $319-$405, showing stability despite a recent daily dip. Year-to-date performance is positive at 3.48%, driven by 11% full-year 2025 revenue growth to over $25 billion TTM, fueled by vascular integrations like Inari Medical and the pending Amplitude Vascular acquisition for intravascular lithotripsy (IVL) technology. Trailing P/E of 40.33 and forward P/E of 22.57, paired with EPS TTM $8.39 and a 1.04% dividend yield, support investor confidence. Recent weeks' sentiment reflects acquisition momentum offsetting cyber and regulatory pressures, with Q1 earnings anticipated soon.
Trending AI Robots
Tickeron’s Trending AI Robots page curates 25 top AI trading bots from a library of 351, tailored for copy trading across stocks, ETFs, and crypto in dynamic market conditions. These bots employ diverse AI/ML strategies like trend following and volatility plays over timeframes from 5 minutes to 55 days, showcasing impressive stats: annualized returns of 15.50% to 167.82%, win rates from 55.35% to 87.72%, and profit factors up to 11.70. Many outperform the S&P 500 with risk metrics like profit-to-drawdown ratios exceeding 20, trading high-momentum tickers in semiconductors, energy, and finance. Traders can subscribe to real-time signals without minimums, matching styles from short-term scalps to multi-asset portfolios. Explore these bots to enhance strategies amid medtech volatility.
Head-to-Head Comparison
In business models, EW emphasizes niche innovation in structural heart procedures, contrasting SYK's diversified exposure across orthopaedics (joint replacements), neurotechnology, and MedSurg equipment sold globally. Growth drivers differ: EW leverages TMTT expansion for high-single-digit procedural increases, while SYK pursues M&A (mergers and acquisitions) in vascular tech for double-digit revenue gains. Recent momentum favors EW's YTD edge, but SYK's scale provides stability with lower forward P/E and dividend support. Risk factors include regulatory hurdles for EW's valve approvals versus SYK's cyber incident exposures; both exhibit low betas (~0.94) signaling sector resilience. Market sentiment tilts toward SYK for broad positioning, while EW appeals for specialized catalysts in aging demographics.
Tickeron AI Verdict
Tickeron’s AI currently leans toward SYK for its superior scale, consistent revenue trajectory, lower forward valuation, and dividend yield, positioning it favorably amid market uncertainties. While EW shows stronger recent momentum and niche growth, SYK's diversification and acquisition pipeline offer probabilistic stability over EW's focused risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EW is a StrongBuy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EW’s FA Score shows that 2 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- EW’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EW’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 3 bullish TA indicator(s).
- EW’s TA Score: 5 bullish, 5 bearish.
- SYK’s TA Score: 3 bullish, 4 bearish.
Price Growth
EW (@Medical/Nursing Services) experienced а -0.46% price change this week, while SYK (@Medical/Nursing Services) price change was -1.06% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
Reported Earning Dates
EW is expected to report earnings on Jul 23, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| EW | SYK | EW / SYK | |
| Capitalization | 50.1B | 119B | 42% |
| EBITDA | 1.56B | 6.44B | 24% |
| Gain YTD | 0.739 | -13.075 | -6% |
| P/E Ratio | 46.42 | 35.27 | 132% |
| Revenue | 6.3B | 25.3B | 25% |
| Total Cash | 3.67B | 2.97B | 124% |
| Total Debt | 703M | 14.7B | 5% |
EW | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 69 | |
SMR RATING 1..100 | 69 | 57 | |
PRICE GROWTH RATING 1..100 | 33 | 62 | |
P/E GROWTH RATING 1..100 | 20 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (9) in the Medical Specialties industry is significantly better than the same rating for EW (81). This means that SYK’s stock grew significantly faster than EW’s over the last 12 months.
SYK's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as EW (100). This means that SYK’s stock grew similarly to EW’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as EW (69). This means that SYK’s stock grew similarly to EW’s over the last 12 months.
EW's Price Growth Rating (33) in the Medical Specialties industry is in the same range as SYK (62). This means that EW’s stock grew similarly to SYK’s over the last 12 months.
EW's P/E Growth Rating (20) in the Medical Specialties industry is somewhat better than the same rating for SYK (80). This means that EW’s stock grew somewhat faster than SYK’s over the last 12 months.
| EW | SYK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | N/A |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 52% |
| Advances ODDS (%) | 8 days ago 59% | 19 days ago 55% |
| Declines ODDS (%) | 12 days ago 59% | 13 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 47% | 2 days ago 47% |
Advertisement
EW and
Correlation & Price change
A.I.dvisor indicates that over the last year, EW has been loosely correlated with ISRG. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EW jumps, then ISRG could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.